Minerva Neurosciences (NERV) EBT (2013 - 2026)
Minerva Neurosciences (NERV) posted EBT of -$32.3 million for Q1 2026, down 466.37% on a QoQ basis from -$5.7 million in Q4 2025, and down 762.9% year-over-year from $4.9 million in Q1 2025.
Minerva Neurosciences (NERV) EBT (2013 - 2026) Analysis & Trends
Minerva Neurosciences' EBT history runs 14 years deep, the most recent figure standing at -$32.3 million for Q1 2026.
- Quarterly EBT fell 762.9% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 143.59% YoY) and the FY2025 annual result came in at -$113.8 million, up 2.4% from the prior year.
- EBT was -$32.3 million for Q1 2026 at Minerva Neurosciences, down from -$5.7 million in the prior quarter.
- Across five years, EBT topped out at -$2.7 million in Q3 2025 and bottomed at -$103.7 million in Q4 2023.
- A 5-year average of -$18.0 million and a median of -$5.9 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT soared 95.83% — and 2026, when it slumped 762.9%.
- Minerva Neurosciences' EBT stood at -$94.9 million in 2022, then decreased by 9.27% to -$103.7 million in 2023, then surged by 95.83% to -$4.3 million in 2024, then slumped by 31.8% to -$5.7 million in 2025, then sank by 466.37% to -$32.3 million in 2026.
- Business Quant data shows NERV's EBT at -$32.3 million in Q1 2026, -$5.7 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -32.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.31 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.33 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.93 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -103.68 Mn |
| Sep 30, 2023 | -6.77 Mn |
| Jun 30, 2023 | -6.18 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -94.88 Mn |
| Sep 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.71 Mn |
| Jun 30, 2021 | -8.98 Mn |